Liraglutide (Victoza), a type 2 diabetes drug, may help prevent peripheral artery disease (PAD) progression, the small, open-label STARDUST trial suggested. Over 6 months, adults with type 2 diabetes ...
The study was partially funded by the PhD programme of Translational Medicine of the University of Campania "Luigi Vanvitelli," Naples, Italy (to Paola Caruso). Three co-authors reported disclosures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback